Acute Kidney Injury During Sickle Cell Crisis
Acute Kidney Injury During Sickle Cell Crisis
批准号:
9788513
负责人:
Jeffrey D Lebensburger
金额:
$7.43万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-19 至 2021-08-31
关键词:
AcuteAcute Renal Failure with Renal Papillary NecrosisAddressAdmission activityAdultAgeAntibioticsApplications GrantsBenefits and RisksBiological AvailabilityBiological MarkersBloodBlood PlateletsCellsChildChildhoodChildhood InjuryChronic Kidney FailureClinicalCohort StudiesCollectionComplementConsentCreatinineDataDevelopmentDiagnosisDiagnosticDiseaseDisease OutcomeDropsEnd stage renal failureEndothelinEndothelin-1EndotheliumEpidemiologyEventFrequenciesFunctional disorderFutureGoalsHemeHemoglobinHemolysisHigh PrevalenceHospitalizationHypoxiaIncidenceInflammatoryInjuryIntervention TrialKidneyKidney DiseasesKnowledgeLaboratoriesLinkMeasuresMediatingMethodologyModelingMonitorNon-Steroidal Anti-Inflammatory AgentsOrganOutputPainParticipantPatientsPharmaceutical PreparationsProtocols documentationRenal Blood FlowReproducibilityResearchRetrospective StudiesRisk FactorsRoleSamplingSerumSickle CellSickle Cell AnemiaStudy modelsSupportive careThalassemiaTherapeuticTherapeutic TrialsUrineVasoconstrictor AgentsVisitWorkacute chest syndromebasebiomarker performanceclinical developmentcohorthigh riskimprovedkidney dysfunctionmortalitymortality riskmouse modelnephrogenesisnephrotoxicitynovel therapeuticspost gamma-globulinspreventprogramssickle cell crisisurinaryvaso-occlusive painvasoconstriction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract:
Sickle cell disease (SCD) patients suffer from repeated episodes of vaso-occlusive pain crisis and acute chest
syndrome, yet data is lacking on the impact of these clinical events on progressive end-organ damage,
including kidney injury. Cell free heme and hemoglobin can be elevated during these hemolytic events.
Murine models suggest that an acute increase in cell free heme and hemoglobin from a hemolytic event will
mediate kidney injury. As it is well recognized the patients with sickle cell suffer from a higher prevalence of
developing kidney injury, it is vital to conduct research to determine the impact of hemolysis during acute SCD
crisis (pain crisis or acute chest syndrome) on the development of kidney injury. We hypothesize that during
SCD crisis, kidney injury occurs and is associated with elevations in cell free heme/hemoglobin and endothelin-
1 levels.
Methodology and Aims: Patients with HbSS and SB0 thalassemia (ages 6-20) admitted for SCD crisis (pain
crisis or acute chest syndrome) will consent to daily first morning urine and blood collection. Urine samples will
be measured for acute kidney injury biomarkers and blood will be measured for cell free heme, hemoglobin,
and endothelin-1. To understand the epidemiology of SCD crisis associated AKI, we will determine the
frequency of AKI as defined by the KDIGO definition (rise in serum creatinine of 0.3mg/dL or 50% from
baseline, or decrease in urine output). We will perform analysis of potential risk factors for kidney injury
including changes in blood counts from baseline and administration of NSAIDs or other nephrotoxic
medications. Second, we still study the pathophysiology of kidney injury during SCD crisis. We will determine
the associations between elevations in cell free heme/hemoglobin and endothelin-1 with the development of
clinical AKI (defined by KDIGO) or subclinical AKI (elevation in urinary biomarkers without a rise in serum
creatinine).
Expected results: At the completion of this R03 proposal, we will establish an association linking hemolysis
during SCD with the development of kidney injury. As sickle cell patients are at increased risk for mortality
from chronic kidney disease, it is imperative to better understand the impact of repeated sickle cell crisis on
kidney injury so that diagnostic, therapeutic, and supportive care protocols for monitoring and preventing AKI
during SCD crisis can be developed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
-
批准号:10244787
-
项目类别:
-
资助金额:$10.74万
-
财政年份:2021
-
负责人:Jeffrey D Lebensburger
-
依托单位:
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
-
批准号:10175027
-
项目类别:
-
资助金额:$69.11万
-
财政年份:2020
-
负责人:Jeffrey D Lebensburger
-
依托单位:
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
-
批准号:10636876
-
项目类别:
-
资助金额:$94.21万
-
财政年份:2020
-
负责人:Jeffrey D Lebensburger
-
依托单位:
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
-
批准号:10029190
-
项目类别:
-
资助金额:$75.62万
-
财政年份:2020
-
负责人:Jeffrey D Lebensburger
-
依托单位:
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
-
批准号:10853502
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2020
-
负责人:Jeffrey D Lebensburger
-
依托单位:
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
-
批准号:10463628
-
项目类别:
-
资助金额:$89.31万
-
财政年份:2020
-
负责人:Jeffrey D Lebensburger
-
依托单位:
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
-
批准号:10462243
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2020
-
负责人:Jeffrey D Lebensburger
-
依托单位:
Chronobiology and Chronopharmacology to Prevent Sickle Cell Nephropathy
-
批准号:9039658
-
项目类别:
-
资助金额:$19.11万
-
财政年份:2015
-
负责人:Jeffrey D Lebensburger
-
依托单位: